Articles

1. Analyses of Basal and Squamous Cell Carcinoma Reported as an Adverse Drug Reaction and Comparison with Cases from the Cancer Registry from Germany

   • Diana Dubrall
   • Bernhardt Sachs
   • Jens Bate

   Original Research Article Open access 19 November 2022 Pages: 21 - 33

   

2. Acknowledgement to Referees

   Acknowledgement to Referees Open access 17 November 2022 Pages: 255 - 256

3. Pharmacokinetics, Bioequivalence and Safety of Cloperastine in Chinese Healthy Subjects Under Fasting and Postprandial Conditions

   • Hong-Yu Luo
   • Hui-Zhi Long
   • Li-Chen Gao

   Original Research Article Open access 11 November 2022 Pages: 311 - 320

   

4. Chinese- and French-Manufactured Immediate-Release Glucophage^® Bioequivalence: A Randomized, Open-Label, Crossover Study

   • Chaoying Hu
   • Dan Gao
   • Lan Zhang

   Original Research Article Open access 20 October 2022 Pages: 301 - 309

   

5. Clinical Validation of the Covariates Pharmacokinetic Model for Propofol in an Adult Population

   • Christopher Hawthorne
   • Martin Shaw
   • Stefan Schraag

   Original Research Article Open access 07 October 2022 Pages: 289 - 300

   

6. Quercetin Supplement to Aspirin Attenuates Lipopolysaccharide-Induced Pre-eclampsia-Like Impairments in Rats Through the NLRP3 Inflammasome

   • Shuangyan Yang
   • Junfeng Zhang
   • Lili Song

   Original Research Article Open access 22 September 2022 Pages: 271 - 279

   

7. Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation

   • Ryohei Ono
   • Kazutaka Nishimura
   • Yoshio Kobayashi

   Original Research Article Open access 14 September 2022 Pages: 281 - 288

   

8. Roxadustat for SARS-CoV-2 Infection: Old Signaling Raised New Hopes

   • Luay Alkazmi
   • Hayder M. Al-kuraishy
   • Jesus Simal-Gandara

   Letter to the Editor Open access 25 August 2022 Pages: 183 - 186

   

9. Novel Strategies for the Treatment of COVID-19

   • Matthew W. McCarthy

   Current Opinion Open access 24 August 2022 Pages: 257 - 262

10. Correction: The Pitfalls of Abnormal Laboratory Value Interpretation in Vaccine Clinical Trials: The Example of Asymptomatic Transient Neutropenia

    • Venanzio Vella
    • Johannes E. Schmidt
    • Joachim Auerbach

    Correction Open access 22 August 2022 Pages: 253 - 253

11. Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study

    • Maki Umemiya
    • Yoshihide Inayama
    • Kenzo Kosaka

    Original Research Article Open access 20 August 2022 Pages: 263 - 269

    

12. Correction: Association between Acid-Suppressive Drugs and Clinical Outcomes in Patients with Nonvalvular Atrial Fibrillation

    • Hideki Arai
    • Shinichiro Ueda
    • Takeshi Morimoto

    Correction Open access 18 August 2022 Pages: 223 - 223

13. Study of the Stability of Sandoz Rituximab Biosimilar Rixathon^®/Riximyo^® When Subjected for up to 21 Days to Ambient Storage

    • Roman Borišek
    • André Mischo
    • Ida Šmid

    Original Research Article Open access 07 August 2022 Pages: 225 - 234

    

14. Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study

    • Andrea Chiricozzi
    • Niccolò Gori
    • ACCURATE Group

    Original Research Article Open access 03 August 2022 Pages: 245 - 252

    

15. Antiplatelets Versus Anticoagulation in Cervical Artery Dissection: A Systematic Review and Meta-analysis of 2064 Patients

    • Abdulrahman Ibrahim Hagrass
    • Bashar Khaled Almaghary
    • Mohamed Fahmy Doheim

    Systematic Review Open access 03 August 2022 Pages: 187 - 203

    

16. Bioavailability of Oniria^®, a Melatonin Prolonged-Release Formulation, Versus Immediate-Release Melatonin in Healthy Volunteers

    • Manuel Román Martinez
    • Eva García Aguilar
    • Dolores Ochoa Mazarro

    Original Research Article Open access 02 August 2022 Pages: 235 - 243

    

17. Association between Acid-Suppressive Drugs and Clinical Outcomes in Patients with Nonvalvular Atrial Fibrillation

    • Hideki Arai
    • Shinichiro Ueda
    • Takeshi Morimoto

    Original Research Article Open access 19 July 2022 Pages: 213 - 222

    

18. Analysis of the US Safety Data for Edaravone (Radicava^®) From the Third Year After Launch

    • Angela Genge
    • Benjamin Rix Brooks
    • Laura Bower

    Original Research Article Open access 20 June 2022 Pages: 205 - 211

19. Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers

    • Yan-ping Liu
    • Ming-hui Hu
    • Yu Cao

    Original Research Article Open access 30 May 2022 Pages: 175 - 182

    

20. Hydroxychloroquine Blood Concentrations Can Be Clinically Relevant Also After Drug Discontinuation

    • Simona De Gregori
    • Francesco Falaschi
    • Antonio Di Sabatino

    Original Research Article Open access 13 May 2022 Pages: 155 - 163

    

21. Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9

    • Theodore J. Kottom
    • Kyle Schaefbauer
    • Andrew H. Limper

    Original Research Article Open access 29 April 2022 Pages: 165 - 173

    

22. Evaluation of the Pharmacokinetics and Safety of AMG 986 Tablet and Capsule Formulations in Healthy Adult Subjects: A Phase I, Open-Label, Randomized Study

    • Ashit Trivedi
    • Y.-H. Kiang
    • Edward Lee

    Original Research Article Open access 12 April 2022 Pages: 147 - 154

    

23. Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease

    • Liangying Gan
    • Panpan Xie
    • Li Zuo

    Original Research Article Open access 05 April 2022 Pages: 119 - 129

    

24. First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants

    • Fumihiko Koiwa
    • Rie Yazawa
    • Tadao Akizawa

    Original Research Article Open access 25 March 2022 Pages: 131 - 140

    

25. A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects

    • Ashit Trivedi
    • Omar Mather
    • Edward Lee

    Original Research Article Open access 13 March 2022 Pages: 141 - 146

    

26. Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections

    • Matthew W. McCarthy

    Review Article Open access 17 February 2022 Pages: 113 - 117

27. Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope

    • Paul Hutson
    • Regis Guieu
    • Mohamed H. Hamdan

    Original Research Article Open access 12 February 2022 Pages: 61 - 70

    

28. An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease

    • Hong Zhang
    • Sami Z. Daoud
    • Yanhua Ding

    Original Research Article Open access 08 February 2022 Pages: 35 - 42

    

29. NLRP3 Inhibitor Tranilast Attenuates Gestational Diabetes Mellitus in a Genetic Mouse Model

    • Jing Cao
    • Qian Peng

    Original Research Article Open access 05 February 2022 Pages: 105 - 112

    

30. In Vitro Stability and Recovery Studies of Pimavanserin in Water and in Different Vehicles Orally Administered

    • Allan David Bokser
    • Yvonne Holmes Adegbenle
    • James C. Norton

    Original Research Article Open access 02 February 2022 Pages: 95 - 104

    

31. Pharmacokinetics of Diazepam and Its Metabolites in Urine of Chinese Participants

    • Le-le Wang
    • Xin-xin Ren
    • Ke-ming Yun

    Original Research Article Open access 31 January 2022 Pages: 43 - 50

    

32. Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986

    • Ashit Trivedi
    • Omar Mather
    • Edward Lee

    Original Research Article Open access 29 January 2022 Pages: 89 - 94

    

33. Bioequivalence and Safety Assessment of Two Formulations of Metformin Hydrochloride Sustained-Release Tablets (Yuantang^® SR and Glucophage^® XR) Under Fed Conditions in Healthy Chinese Adult Subjects: An Open-Label, Two-Way Crossover, Sequence Randomized Phase I Clinical Trial

    • Ming-Li Sun
    • Hui-Juan Liu
    • Xinghe Wang

    Original Research Article Open access 21 January 2022 Pages: 51 - 60

    

34. A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects

    • Yoomin Jeon
    • Nora Lee
    • Howard Lee

    Original Research Article Open access 06 January 2022 Pages: 71 - 87

    

35. Pharmacokinetics and Pharmacodynamics of Ibrexafungerp

    • Matthew William McCarthy

    Review Article Open access 27 December 2021 Pages: 9 - 13

36. The Pitfalls of Abnormal Laboratory Value Interpretation in Vaccine Clinical Trials: The Example of Asymptomatic Transient Neutropenia

    • Venanzio Vella
    • Johannes E. Schmidt
    • Joachim Auerbach

    Current Opinion Open access 18 December 2021 Pages: 1 - 8

    

37. Pharmacokinetics and Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Study

    • Ping Shi
    • Xin Liu
    • Yu Cao

    Original Research Article Open access 30 November 2021 Pages: 15 - 23

    

38. Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial

    • Tal Y. Samuel
    • Tal Hasin
    • David Leibowitz

    Original Research Article Open access 26 November 2021 Pages: 25 - 33

    

39. The Anti-inflammatory Effect of Dexmedetomidine Administration on Patients Undergoing Intestinal Surgery: A Randomized Study

    • Rushuang Chen
    • Zhenming Kang
    • Shunyuan Li

    Original Research Article Open access 09 November 2021 Pages: 445 - 453

    

40. Acknowledgement to Referees

    Acknowledgement to Referees Open access 09 November 2021 Pages: 359 - 360

41. Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection

    • Sneha V. Gupta
    • Marie C. Fanget
    • Erik Mogalian

    Original Research Article Open access 06 November 2021 Pages: 455 - 465

    

42. Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration

    • John Dodd
    • Robert Jordan
    • Carl Spana

    Original Research Article Open access 25 October 2021 Pages: 431 - 443

    

43. Author’s Reply to Petersen: “Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS”

    • Igor V. Maev
    • Yury A. Kucheryavyy
    • J. Enrique Dominguez‑Munoz

    Letter to the Editor Open access 23 October 2021 Pages: 469 - 470

44. Comment on: “Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS”

    • Karl-Uwe Petersen

    Letter to the Editor Open access 20 October 2021 Pages: 467 - 468

45. Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study

    • Kimitaka Suetsugu
    • Shota Muraki
    • Ichiro Ieiri

    Original Research Article Open access 15 October 2021 Pages: 419 - 429

    

46. Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus

    • Xuan Zhou
    • Tsung-I Lee
    • Peiming Ma

    Original Research Article Open access 09 October 2021 Pages: 407 - 417

    

47. Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy

    • Pauline Vaflard
    • Xavier Paoletti
    • Christophe Le Tourneau

    Original Research Article Open access 25 September 2021 Pages: 399 - 406

    

48. The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process

    • Aneal Khan
    • Sandra M. Sirrs
    • the Canadian Fabry Disease Initiative

    Original Research Article Open access 20 September 2021 Pages: 385 - 397

    

49. Improvement of Intranasal Drug Delivery with Intravail^® Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System

    • Adrian L. Rabinowicz
    • Enrique Carrazana
    • Edward T. Maggio

    Review Article Open access 25 August 2021 Pages: 361 - 369

    

50. Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

    • Charles E. Frost
    • Van Ly
    • Samira M. Garonzik

    Original Research Article Open access 07 August 2021 Pages: 375 - 384